Efficacy Analysis of PTCD + TACE vs PTCD + Apatinib in the Treatment of HCC with Obstructive Jaundice: A Retrospective Study


Cite item

Full Text

Abstract

Purpose:The aim was to evaluate the safety and effectiveness of PTCD combined with TACE in the treatment of hepatocellular carcinoma with obstructive jaundice and to compare the efficacy of TACE in patients with different levels of bilirubin after PTCD.

Methods:The clinical data of 141 patients with HCC complicated with obstructive jaundice were analyzed retrospectively. The patients underwent PTCD first. When the total bilirubin decreased, the patients received TACE or Apatinib treatment. They were divided into two groups: (1) PTCD+TACE group, N=68; (2) PTCD+Apatinib group, N=73.

Results:The PTCD+TACE group had higher ORR and DCR than the PTCD+Apatinib group (57.4% vs 12.3%, p < 0.001; 80.9% vs 60.3%, p = 0.010). The mPFS of the PTCD+TACE group was longer than that of the PTCD+Apatinib group (7.1 months vs 3.8 months, p < 0.001). The mOS of the PTCD+TACE group was longer than that of the PTCD+Apatinib group(11.5 months vs 7.7 months, p < 0.001). In the subgroup analysis of the PTCD+TACE group, the results showed that the survival benefits of the groups with total bilirubip <0 times and 2-3 times were greater.

Conclusion::In patients with HCC and obstructive jaundice, superselective TACE(lipiodol+epirubicin emulsion) significantly prolonged OS and PFS compared with Apatinib after using PTCD to reduce total bilirubin tp <000 µmol/L. Patients whose total bilirubin dropped to ≤3 times of the upper limit of normal value after PTCD had longer OS and PFS than patients >3 times.

About the authors

Haohao Lu

Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Email: info@benthamscience.net

Bin Liang

Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Email: info@benthamscience.net

Xiangwen Xia

Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Email: info@benthamscience.net

Chuansheng Zheng

Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Author for correspondence.
Email: info@benthamscience.net

References

  1. Chidambaranathan-Reghupaty, S.; Fisher, P.B.; Sarkar, D. Hepatocellular carcinoma (HCC): Epidemiology, etiology and molecular classification. Adv. Cancer Res., 2021, 149, 1-61. doi: 10.1016/bs.acr.2020.10.001 PMID: 33579421
  2. Kulik, L.; El-Serag, H.B. Epidemiology and management of hepatocellular carcinoma. Gastroenterology, 2019, 156(2), 477-491.e1. doi: 10.1053/j.gastro.2018.08.065 PMID: 30367835
  3. Yang, J.D.; Hainaut, P.; Gores, G.J.; Amadou, A.; Plymoth, A.; Roberts, L.R. A global view of hepatocellular carcinoma: Trends, risk, prevention and management. Nat. Rev. Gastroenterol. Hepatol., 2019, 16(10), 589-604. doi: 10.1038/s41575-019-0186-y PMID: 31439937
  4. Dimitroulis, D.; Damaskos, C.; Valsami, S.; Davakis, S.; Garmpis, N.; Spartalis, E.; Athanasiou, A.; Moris, D.; Sakellariou, S.; Kykalos, S.; Tsourouflis, G.; Garmpi, A.; Delladetsima, I.; Kontzoglou, K.; Kouraklis, G. From diagnosis to treatment of hepatocellular carcinoma: An epidemic problem for both developed and developing world. World J. Gastroenterol., 2017, 23(29), 5282-5294. doi: 10.3748/wjg.v23.i29.5282 PMID: 28839428
  5. Woo, H.Y.; Han, S.Y.; Heo, J.; Kim, D.U.; Baek, D.H.; Yoo, S.Y.; Kim, C.W.; Kim, S.; Song, G.A.; Cho, M.; Kang, D.H. Role of endoscopic biliary drainage in advanced hepatocellular carcinoma with jaundice. PLoS One, 2017, 12(11), e0187469. doi: 10.1371/journal.pone.0187469 PMID: 29095941
  6. Minami, Y.; Kudo, M. Hepatocellular carcinoma with obstructive jaundice: endoscopic and percutaneous biliary drainage. Dig. Dis., 2012, 30(6), 592-597. doi: 10.1159/000343087 PMID: 23258100
  7. Qin, L.X.; Tang, Z.Y. Hepatocellular carcinoma with obstructive jaundice: Diagnosis, treatment and prognosis. World J. Gastroenterol., 2003, 9(3), 385-391. doi: 10.3748/wjg.v9.i3.385 PMID: 12632482
  8. Suh, Y.G.; Kim, D.Y.; Han, K.H.; Seong, J. Effective biliary drainage and proper treatment improve outcomes of hepatocellular carcinoma with obstructive jaundice. Gut Liver, 2014, 8(5), 526-535. doi: 10.5009/gnl13370 PMID: 25071072
  9. Park, S.; Park, J.Y.; Chung, M.J.; Chung, J.B.; Park, S.W.; Han, K.H.; Song, S.Y.; Bang, S. The efficacy of endoscopic palliation of obstructive jaundice in hepatocellular carcinoma. Yonsei Med. J., 2014, 55(5), 1267-1272. doi: 10.3349/ymj.2014.55.5.1267 PMID: 25048484
  10. Tanaka, T.; Kuzuya, T.; Ishigami, M.; Ito, T.; Ishizu, Y.; Honda, T.; Ishikawa, T.; Fujishiro, M. Efficacy and safety of sorafenib in unresectable hepatocellular carcinoma with bile duct invasion. Oncology, 2020, 98(9), 621-629. doi: 10.1159/000507051 PMID: 32434180
  11. Lai, E.C.H.; Yee Lau, W. Hepatocellular carcinoma presenting with obstructive jaundice. ANZ J. Surg., 2006, 76(7), 631-636. doi: 10.1111/j.1445-2197.2006.03794.x PMID: 16813631
  12. Galle, P.R.; Forner, A.; Llovet, J.M.; Mazzaferro, V.; Piscaglia, F.; Raoul, J-L.; Schirmacher, P.; Vilgrain, V. European association for the study of the liver. EASL clinical practice guidelines: Management of hepatocellular carcinoma. J. Hepatol., 2018, 69(1), 182-236. doi: 10.1016/j.jhep.2018.03.019 PMID: 29628281
  13. Sugiyama, G.; Okabe, Y.; Ishida, Y.; Saitou, F.; Kawahara, R.; Ishikawa, H.; Horiuchi, H.; Kinoshita, H.; Tsuruta, O.; Sata, M. Evaluation of endoscopic biliary stenting for obstructive jaundice caused by hepatocellular carcinoma. World J. Gastroenterol., 2014, 20(22), 6968-6973. doi: 10.3748/wjg.v20.i22.6968 PMID: 24944490
  14. An, J.; Lee, K.S.; Kim, K.M.; Park, D.H.; Lee, S.S.; Lee, D.; Shim, J.H.; Lim, Y.S.; Lee, H.C.; Chung, Y.H.; Lee, Y.S. Clinical features and outcomes of patients with hepatocellular carcinoma complicated with bile duct invasion. Clin. Mol. Hepatol., 2017, 23(2), 160-169. doi: 10.3350/cmh.2016.0088 PMID: 28506055
  15. Reig, M.; Forner, A.; Rimola, J.; Ferrer-Fàbrega, J.; Burrel, M.; Garcia-Criado, Á.; Kelley, R.K.; Galle, P.R.; Mazzaferro, V.; Salem, R.; Sangro, B.; Singal, A.G.; Vogel, A.; Fuster, J.; Ayuso, C.; Bruix, J. BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. J. Hepatol., 2022, 76(3), 681-693. doi: 10.1016/j.jhep.2021.11.018 PMID: 34801630
  16. Na, S.K.; Yim, S.Y.; Suh, S.J.; Jung, Y.K.; Kim, J.H.; Seo, Y.S.; Yim, H.J.; Yeon, J.E.; Byun, K.S.; Um, S.H. ALBI versus Child-Pugh grading systems for liver function in patients with hepatocellular carcinoma. J. Surg. Oncol., 2018, 117(5), 912-921. doi: 10.1002/jso.24992 PMID: 29448306
  17. Han, K.; Kim, J.H. Transarterial chemoembolization in hepatocellular carcinoma treatment: Barcelona clinic liver cancer staging system. World J. Gastroenterol., 2015, 21(36), 10327-10335. doi: 10.3748/wjg.v21.i36.10327 PMID: 26420959
  18. Goldstein, H.M.; Wallace, S.; Anderson, J.H.; Bree, R.L.; Gianturco, C. Transcatheter occlusion of abdominal tumors. Radiology, 1976, 120(3), 539-545. doi: 10.1148/120.3.539 PMID: 948584
  19. Petruzzi, P.; Crocetti, L.; Lencioni, R. Chemoembolization of hepatocellular carcinoma. Semin. Intervent. Radiol.,, 2013, 30(1), 003-011. doi: 10.1055/s-0033-1333648 PMID: 24436512
  20. Sieghart, W.; Hucke, F.; Peck-Radosavljevic, M. Transarterial chemoembolization: Modalities, indication, and patient selection. J. Hepatol., 2015, 62(5), 1187-1195. doi: 10.1016/j.jhep.2015.02.010 PMID: 25681552
  21. Li, S.; He, X.; Dang, L.; Xu, F.; Fang, J.; Li, F.; Wang, W. Efficacy of 125I versus Non-125I combined with transcatheter arterial chemoembolization for the treatment of unresectable hepatocellular carcinoma with obstructive jaundice. Dig. Dis. Sci., 2018, 63(2), 321-328. doi: 10.1007/s10620-017-4899-x PMID: 29305738
  22. Young, S.; Sanghvi, T.; Lake, J.J.; Rubin, N.; Golzarian, J. Predicting post-transarterial chemoembolization outcomes: A comparison of direct and total bilirubin serums levels. Diagn. Interv. Imaging, 2020, 101(6), 355-364. doi: 10.1016/j.diii.2019.12.006 PMID: 31948887
  23. Thorat, A.; Lee, C.F.; Wu, T.H.; Chan, K.M.; Chou, H.S.; Lee, W.C. Safety of transarterial chemoembolization as bridging therapy in HCC patients with hyperbilirubinemia on the waiting list for liver transplantation: A centre experience. Hepatogastroenterology, 2013, 60(128), 2076-2079. PMID: 24719950
  24. Chandrashekhara, S.H.; Gamanagatti, S.; Singh, A.; Bhatnagar, S. Current status of percutaneous transhepatic biliary drainage in palliation of malignant obstructive jaundice: A review. Indian J. Palliat. Care, 2016, 22(4), 378-387. doi: 10.4103/0973-1075.191746 PMID: 27803558
  25. Sun, J.J.; Wang, K.; Zhang, C.Z.; Guo, W.X.; Shi, J.; Cong, W.M.; Wu, M.C.; Lau, W.Y.; Cheng, S.Q. Postoperative adjuvant transcatheter arterial chemoembolization after R0 hepatectomy improves outcomes of patients who have hepatocellular carcinoma with microvascular invasion. Ann. Surg. Oncol., 2016, 23(4), 1344-1351. doi: 10.1245/s10434-015-5008-z PMID: 26714945
  26. Llovet, J.M.; Lencioni, R. mRECIST for HCC: Performance and novel refinements. J. Hepatol., 2020, 72(2), 288-306. doi: 10.1016/j.jhep.2019.09.026 PMID: 31954493
  27. Tian, T.; Guo, J.; Hu, J.L.; Hu, Y.; Guo, P.; Yu, X.Y. Advanced hepatocellular carcinoma and palliative care: a scoping review. BMJ Support. Palliat. Care, 2022, 14(2), 163-170. doi: 10.1136/spcare-2022-003798 PMID: 36396345
  28. Rammohan, A.; Sathyanesan, J.; Rajendran, K.; Pitchaimuthu, A.; Perumal, S.K.; Balaraman, K.; Ramasamy, R.; Palaniappan, R.; Govindan, M. Bile duct thrombi in hepatocellular carcinoma: Is aggressive surgery worthwhile? HPB (Oxford), 2015, 17(6), 508-513. doi: 10.1111/hpb.12383 PMID: 25639610
  29. Fargo, M.V.; Grogan, S.P.; Saguil, A. Evaluation of jaundice in adults. Am. Fam. Physician, 2017, 95(3), 164-168. PMID: 28145671
  30. Bhattarai, S.; Graham, R.P.; Sigel, C.S.; Shi, J.; Gonzalez, R.S.; Xue, Y.; Krasinskas, A.M. HooKim, K.; Adsay, V.; Reid, M.D. Bile duct involvement by hepatocellular carcinoma: A rare occurrence and poor prognostic indicator in bile duct brushing samples. Cancer Cytopathol., 2019, 127(11), 691-699. doi: 10.1002/cncy.22185 PMID: 31518056
  31. Jeon, SH.; Park, KS.; Kim, YH.; Shin, YS.; Kang, MK.; Jang, BK.; Chung, WJ.; Cho, KB.; Hwang, JS. Incidence and risk factors of acute hepatic failure after transcatheter arterial chemoembolization for hepatocellular carcinoma. Korean J. Gastroenterol., 2007, 50(3), 176-182. doi: 10.1111/ecc.12858 PMID: 17885283
  32. Tong, D.; Wu, L.; Chen, X.; Li, Y. Post-operative care of interventional therapy for 40 liver cancer patients with obstructive jaundice. Eur. J. Cancer Care (Engl.), 2018, 27(4), e12858. doi: 10.1111/ecc.12858 PMID: 29767833
  33. Zhang, C.; Yang, Y.; Wu, P.; Ma, Y.; Zhang, H.; Lin, M.; Shi, L.; Li, J.; Zhao, M. Prevention and treatment of complications for full-covered self-expanding removable metal stents in malignant obstructive jaundice. Zhonghua Yi Xue Za Zhi, 2015, 95(6), 416-419. PMID: 25916776
  34. Sacco, R.; Tapete, G.; Simonetti, N.; Sellitri, R.; Natali, V.; Melissari, S.; Cabibbo, G.; Biscaglia, L.; Bresci, G.; Giacomelli, L. Transarterial chemoembolization for the treatment of hepatocellular carcinoma: A review. J. Hepatocell. Carcinoma, 2017, 4, 105-110. doi: 10.2147/JHC.S103661 PMID: 28795053
  35. Khalid, M.A.; Achakzai, I.K.; Hanif, F.M.; Ahmed, S.; Majid, Z.; Luck, N.H. To determine the prognostic value of the albumin-bilirubin grade (ALBI) in patients underwent transarterial chemoembolization for unresectable hepatocellular carcinoma. Gastroenterol. Hepatol. Bed Bench, 2019, 12(2), 110-115. PMID: 31191834
  36. Li, L.; Mo, F.; Hui, E.P.; Chan, S.L.; Koh, J.; Tang, N.L.S.; Yu, S.C.H.; Yeo, W. The association of liver function and quality of life of patients with liver cancer. BMC Gastroenterol., 2019, 19(1), 66. doi: 10.1186/s12876-019-0984-2 PMID: 31046687
  37. Tellapuri, S.; Sutphin, P.D.; Beg, M.S.; Singal, A.G.; Kalva, S.P. Staging systems of hepatocellular carcinoma: A review. Indian J. Gastroenterol., 2018, 37(6), 481-491. doi: 10.1007/s12664-018-0915-0 PMID: 30593649
  38. Bruix, J.; Reig, M.; Sherman, M. Evidence-based diagnosis, staging, and treatment of patients with hepatocellular carcinoma. Gastroenterology, 2016, 150(4), 835-853. doi: 10.1053/j.gastro.2015.12.041 PMID: 26795574
  39. Díaz-González, Á.; Reig, M.; Bruix, J. Treatment of hepatocellular carcinoma. Dig. Dis., 2016, 34(5), 597-602. doi: 10.1159/000445275 PMID: 27332893
  40. Liang, X.; Liangliang, X.; Peng, W.; Tao, Y.; Jinfu, Z.; Ming, Z.; Mingqing, X. Combined prognostic nutritional index and albumin-bilirubin grade to predict the postoperative prognosis of HBV-associated hepatocellular carcinoma patients. Sci. Rep., 2021, 11(1), 14624. doi: 10.1038/s41598-021-94035-5 PMID: 34272447
  41. Brown, D.B.; Fundakowski, C.E.; Lisker-Melman, M.; Crippin, J.S.; Pilgram, T.K.; Chapman, W.; Darcy, M.D. Comparison of MELD and Child-Pugh scores to predict survival after chemoembolization for hepatocellular carcinoma. J. Vasc. Interv. Radiol., 2004, 15(11), 1209-1218. doi: 10.1097/01.RVI.0000128123.04554.C1 PMID: 15525739
  42. Cabibbo, G.; Genco, C.; Di Marco, V.; Barbara, M.; Enea, M.; Parisi, P.; Brancatelli, G.; Romano, P.; Craxì, A.; Cammà, C. Predicting survival in patients with hepatocellular carcinoma treated by transarterial chemoembolisation. Aliment. Pharmacol. Ther., 2011, 34(2), 196-204. doi: 10.1111/j.1365-2036.2011.04694.x PMID: 21564144
  43. Choi, J.; Ryu, J.K.; Lee, S.H.; Ahn, D.W.; Hwang, J.H.; Kim, Y.T.; Yoon, Y.B.; Han, J.K. Biliary drainage for obstructive jaundice caused by unresectable hepatocellular carcinoma: the endoscopic versus percutaneous approach. Hepatobiliary Pancreat. Dis. Int., 2012, 11(6), 636-642. doi: 10.1016/S1499-3872(12)60237-9 PMID: 23232636
  44. Cho, H.C.; Lee, J.K.; Lee, K.H.; Lee, K.T.; Paik, S.; Choo, S.W.; Do, Y.S.; Choo, I.W. Are endoscopic or percutaneous biliary drainage effective forobstructive jaundice caused by hepatocellular carcinoma? Eur. J. Gastroenterol. Hepatol., 2011, 23(3), 224-231. doi: 10.1097/MEG.0b013e3283436ff6 PMID: 21228705
  45. Bao, G.; Liu, H.; Ma, Y.; Li, N.; Lv, F.; Dong, X.; Chen, X. The clinical efficacy and safety of different biliary drainages in malignant obstructive jaundice treatment. Am. J. Transl. Res., 2021, 13(6), 7400-7405. PMID: 34306512
  46. Alatise, O.; Owojuyigbe, A.; Omisore, A.; Ndububa, D.; Aburime, E.; Dua, K.; Asombang, A. Endoscopic management and clinical outcomes of obstructive jaundice. Niger. Postgrad. Med. J., 2020, 27(4), 302-310. doi: 10.4103/npmj.npmj_242_20 PMID: 33154282
  47. Zerem, E.; Imširović, B.; Kunosić, S.; Zerem, D.; Zerem, O. Percutaneous biliary drainage for obstructive jaundice in patients with inoperable, malignant biliary obstruction. Clin. Exp. Hepatol., 2022, 8(1), 70-77. doi: 10.5114/ceh.2022.114190 PMID: 35415254
  48. Duan, F.; Cui, L.; Bai, Y.; Li, X.; Yan, J.; Liu, X. Comparison of efficacy and complications of endoscopic and percutaneous biliary drainage in malignant obstructive jaundice: A systematic review and meta-analysis. Cancer Imaging, 2017, 17(1), 27. doi: 10.1186/s40644-017-0129-1 PMID: 29037223
  49. Rizzo, A.; Ricci, A.D.; Frega, G.; Palloni, A.; De Lorenzo, S.; Abbati, F.; Mollica, V.; Tavolari, S.; Di Marco, M.; Brandi, G. How to choose between percutaneous transhepatic and endoscopic biliary drainage in malignant obstructive jaundice: An updated systematic review and meta-analysis. In Vivo, 2020, 34(4), 1701-1714. doi: 10.21873/invivo.11964 PMID: 32606139
  50. Liu, Y.M.; Ren, Y.Q.; Song, S.L.; Zheng, C.S. Pyogenic liver abscess in non-liver cancer patients and liver cancer patients treated with TACE: Etiological characteristics, treatment, and outcome analysis. Kaohsiung J. Med. Sci., 2022. doi: 10.1002/kjm2.12613 PMID: 36354204
  51. Lv, W.F.; Lu, D.; He, Y.S.; Xiao, J.K.; Zhou, C.Z.; Cheng, D.L. Liver abscess formation following transarterial chemoembolization. Medicine (Baltimore), 2016, 95(17), e3503. doi: 10.1097/MD.0000000000003503 PMID: 27124055
  52. Scartozzi, M.; Baroni, G.S.; Faloppi, L.; Paolo, M.D.P.; Pierantoni, C.; Candelari, R.; Berardi, R.; Antognoli, S.; Mincarelli, C.; Risaliti, A.; Marmorale, C.; Antico, E.; Benedetti, A.; Cascinu, S. Trans-arterial chemo-embolization (TACE), with either lipiodol (traditional TACE) or drug-eluting microspheres (precision TACE, pTACE) in the treatment of hepatocellular carcinoma: Efficacy and safety results from a large mono-institutional analysis. J. Exp. Clin. Cancer Res., 2010, 29(1), 164. doi: 10.1186/1756-9966-29-164 PMID: 21159184
  53. Mohammadifard, M.; Ghanaati, H.; Mohammadifard, M. A review of applying transarterial chemoembolization (TACE) method for management of hepatocellular carcinoma. J. Family Med. Prim. Care, 2021, 10(10), 3553-3560. doi: 10.4103/jfmpc.jfmpc_2347_20 PMID: 34934646
  54. Dai, Q.S.; Gu, H.L.; Ye, S.; Zhang, Y.J.; Lin, X.J.; Lau, W.Y.; Peng, Z.W.; Chen, M.S. Transarterial chemoembolization vs. conservative treatment for unresectable infiltrating hepatocellular carcinoma: A retrospective comparative study. Mol. Clin. Oncol., 2014, 2(6), 1047-1054. doi: 10.3892/mco.2014.391 PMID: 25279196
  55. Kong, J.Y.; Li, S.M.; Fan, H.Y.; Zhang, L.; Zhao, H.J.; Li, S.M. Transarterial chemoembolization extends long-term survival in patients with unresectable hepatocellular carcinoma. Medicine (Baltimore), 2018, 97(33), e11872. doi: 10.1097/MD.0000000000011872 PMID: 30113483
  56. Lu, J.; Zhao, M.; Arai, Y.; Zhong, B.Y.; Zhu, H.D.; Qi, X.L.; Baere, T.; Pua, U.; Yoon, H.K.; Madoff, D.C.; Teng, G.J. Clinical practice of transarterial chemoembolization for hepatocellular carcinoma: Consensus statement from an international expert panel of International Society of Multidisciplinary Interventional Oncology (ISMIO). Hepatobiliary Surg. Nutr., 2021, 10(5), 661-671. doi: 10.21037/hbsn-21-260 PMID: 34760969
  57. Lee, J.W.; Han, J.K.; Kim, T.K.; Choi, B.I.; Park, S.H.; Ko, Y.H.; Yoon, C.J.; Yeon, K.M. Obstructive jaundice in hepatocellular carcinoma: response after percutaneous transhepatic biliary drainage and prognostic factors. Cardiovasc. Intervent. Radiol., 2002, 25(3), 176-179. doi: 10.1007/s00270-001-0100-0 PMID: 12058212
  58. Park, K.H.; Kim, J.H.; Choe, W.H.; Kwon, S.Y.; Yoo, B.C.; Hwang, J.H.; Park, S.W.; Kim, Y.J.; Park, H.S.; Yu, M.H.; Jeon, H.J. Risk factors for liver function deterioration after transarterial chemoembolization refractoriness in child-pugh class a hepatocellular carcinoma patients. Korean J. Gastroenterol., 2020, 75(3), 147-156. doi: 10.4166/kjg.2020.75.3.147 PMID: 32209803
  59. Chen, Y.; Yan, Z.P.; Wang, J.H.; Wang, X.L.; Cheng, J.M.; Gong, G.Q.; Liu, Q.X.; Qian, S.; Liu, R.; Luo, J.J. Epirubicin in the treatment of malignant obstructive jaundice. Zhonghua Zhong Liu Za Zhi, 2006, 28(5), 397-399. PMID: 17045011
  60. Li, M.Q.; Zhang, J.X.; Lu, C.H.; Pan, H.; Ru, F.M.; Cao, C.W.; Xu, J.C.; Xu, J.H. Long-term outcome of interventional therapy for malignant biliary obstruction: A retrospective analysis of 109 cases. Zhonghua Yi Xue Za Zhi, 2008, 88(39), 2743-2747. PMID: 19080446
  61. Tian, S.; Quan, H.; Xie, C.; Guo, H.; Lü, F.; Xu, Y.; Li, J.; Lou, L. YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase with potent activity in vitro and in vivo. Cancer Sci., 2011, 102(7), 1374-1380. doi: 10.1111/j.1349-7006.2011.01939.x PMID: 21443688
  62. Yu, W.C.; Zhang, K.Z.; Chen, S.G.; Liu, W.F. Efficacy and Safety of apatinib in patients with intermediate/advanced hepatocellular carcinoma. Medicine (Baltimore), 2018, 97(3), e9704. doi: 10.1097/MD.0000000000009704 PMID: 29505026
  63. Wang, Y.; Gou, Q.; Xu, R.; Chen, X.; Zhou, Z. Efficacy and safety of sorafenib versus apatinib in the treatment of intermediate and advanced hepatocellular carcinoma: A comparative retrospective study. OncoTargets Ther., 2018, 11, 3407-3413. doi: 10.2147/OTT.S161023 PMID: 29928132
  64. Zhen, L.; Jiali, C.; Yong, F.; Han, X.; Hongming, P.; Weidong, H. The efficacy and safety of apatinib treatment for patients with unresectable or relapsed liver cancer: A retrospective study. J. Cancer, 2018, 9(16), 2773-2777. doi: 10.7150/jca.26376 PMID: 30123344
  65. Hu, Y.; Lin, H.; Hao, M.; Zhou, Y.; Chen, Q.; Chen, Z. Efficacy and safety of apatinib in treatment of unresectable intrahepatic cholangiocarcinoma: An observational study. Cancer Manag. Res., 2020, 12, 5345-5351. doi: 10.2147/CMAR.S254955 PMID: 32753952
  66. Shimohira, M.; Ogino, H.; Kawai, T.; Sakurai, K.; Nakagawa, M.; Shibamoto, Y. Clinical usefulness of the triaxial system in super-selective transcatheter arterial chemoembolization for hepatocellular carcinoma. Acta Radiol., 2012, 53(8), 857-861. doi: 10.1258/ar.2012.120044 PMID: 22850577
  67. Choi, J.W.; Chung, J.W.; Cho, Y.K.; Kim, Y.J.; Yoon, J.H.; Kim, H.C.; Jae, H.J. Transarterial chemoembolization for hepatocellular carcinomas with central bile duct invasion: Safety, prognosis, and predictive factors. Cardiovasc. Intervent. Radiol., 2015, 38(4), 937-945. doi: 10.1007/s00270-014-1032-9 PMID: 25465065
  68. Bannangkoon, K.; Hongsakul, K.; Tubtawee, T.; Mc Neil, E.; Sriplung, H.; Chongsuwiwatvong, V. Rate and predictive factors for sustained complete response after selective transarterial chemoembolization (TACE) in patients with hepatocellular carcinoma. Asian Pac. J. Cancer Prev., 2018, 19(12), 3545-3550. doi: 10.31557/APJCP.2018.19.12.3545 PMID: 30583681
  69. Sacco, R.; Bertini, M.; Petruzzi, P.; Bertoni, M.; Bargellini, I.; Bresci, G.; Federici, G.; Gambardella, L.; Metrangolo, S.; Parisi, G.; Romano, A.; Scaramuzzino, A.; Tumino, E.; Silvestri, A.; Altomare, E.; Vignali, C.; Capria, A. Clinical impact of selective transarterial chemoembolization on hepatocellular carcinoma: A cohort study. World J. Gastroenterol., 2009, 15(15), 1843-1848. doi: 10.3748/wjg.15.1843 PMID: 19370781
  70. Yan, L.; Ren, Y.; Qian, K.; Kan, X.; Zhang, H.; Chen, L.; Liang, B.; Zheng, C. Superselective transarterial chemoembolization for unresectable or "ablation unsuitable" hepatocellular carcinoma in the caudate lobe: A real world, single-center retrospective study. Front. Oncol., 2021, 11, 678847. doi: 10.3389/fonc.2021.678847 PMID: 34778023
  71. Inui, K.; Takahashi, Y.; Komeichi, H.; Katsuta, Y.; Shimizu, S.; Mizuno, K. Successful transcatheter chemoembolization for acute jaundice in a patient with advanced hepatocellular carcinoma and portal vein tumor thrombosis: A case report. J. Nippon Med. Sch., 2009, 76(4), 217-220. doi: 10.1272/jnms.76.217 PMID: 19755798
  72. Choi, J.; Ryu, J.K.; Lee, S.H.; Hwang, J.H.; Ahn, D.W.; Kim, Y.T.; Yoon, Y.B.; Yoon, C.J.; Kang, S.G.; Chung, J.W. Palliative treatment of unresectable hepatocellular carcinoma with obstructive jaundice using biliary drainage with subsequent transarterial chemoembolization. J. Palliat. Med., 2013, 16(9), 1026-1033. doi: 10.1089/jpm.2013.0067 PMID: 23888306
  73. Olivo, M.; Valenza, F.; Buccellato, A.; Scala, L.; Virdone, R.; Sciarrino, E.; Di Piazza, S.; Marrone, C.; Orlando, A.; Fusco, G.; Madonia, S.; Cottone, M. Transcatheter arterial chemoembolisation for hepatocellular carcinoma in cirrhosis: Survival rate and prognostic factors. Dig. Liver Dis., 2010, 42(7), 515-519. doi: 10.1016/j.dld.2009.09.012 PMID: 19914153

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2024 Bentham Science Publishers